Eagle Pharmaceuticals (NASDAQ:EGRX) Shares Pass Above Fifty Day Moving Average – Here’s What Happened

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) passed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $1.33 and traded as high as $1.80. Eagle Pharmaceuticals shares last traded at $1.80, with a volume of 280 shares traded.

Wall Street Analysts Forecast Growth

Separately, StockNews.com started coverage on Eagle Pharmaceuticals in a research note on Tuesday. They set a “hold” rating on the stock.

Eagle Pharmaceuticals Stock Performance

The stock’s 50-day moving average is $1.33 and its two-hundred day moving average is $0.93.

Institutional Investors Weigh In On Eagle Pharmaceuticals

An institutional investor recently raised its position in Eagle Pharmaceuticals stock. DGS Capital Management LLC increased its stake in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) by 44.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 71,728 shares of the specialty pharmaceutical company’s stock after acquiring an additional 22,239 shares during the period. DGS Capital Management LLC owned approximately 0.55% of Eagle Pharmaceuticals worth $268,000 as of its most recent SEC filing. 85.36% of the stock is currently owned by hedge funds and other institutional investors.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.